DA-EPOCH-R was scheduled to be administered with CNS prophylaxis for six cycles.
2
Interpretation: In this study, DA-EPOCH-R produced durable remission in patients with MYC-rearranged aggressive B-cell lymphomas and should be considered for the treatment of these diseases.
3
Methods: A total of 252 cases treated with R-CHOP and 146 cases who received DA-EPOCH-R were enrolled into this study.